Sei Investments Co. Has $9.35 Million Holdings in Bruker Corporation $BRKR

Posted by Francis Steltz on Aug 2nd, 2026

Sei Investments Co. increased its holdings in Bruker Corporation (NASDAQ:BRKR – Free Report) by 19.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 258,901 shares of the medical research company’s stock after buying an additional 42,781 shares during the period. Sei Investments Co.’s holdings in Bruker were worth $9,351,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Orbis Allan Gray Ltd grew its position in Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after buying an additional 761,258 shares in the last quarter. State Street Corp raised its holdings in Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after acquiring an additional 91,706 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the period. Sculptor Capital LP lifted its position in shares of Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after acquiring an additional 476,363 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after acquiring an additional 2,289,269 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. UBS Group set a $60.00 price target on Bruker in a report on Wednesday, June 24th. Citigroup upped their price objective on Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, JPMorgan Chase & Co. boosted their target price on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $56.79.

Read Our Latest Research Report on BRKR

Bruker Stock Performance

NASDAQ BRKR opened at $62.84 on Friday. The firm’s fifty day moving average price is $58.15 and its two-hundred day moving average price is $46.66. The stock has a market cap of $9.57 billion, a PE ratio of -261.83, a PEG ratio of 2.01 and a beta of 1.29. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55.

Bruker (NASDAQ:BRKR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same period in the prior year, the business earned $0.47 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio is presently -83.33%.

Bruker Company Profile

(Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.